Loading
A phase 2 trial of tislelizumab and anlotinib in lung cancer, run by Yantai Yuhuangding Hospital, now recruiting.
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC is a phase 2, interventional study registered as NCT07815223 by Yantai Yuhuangding Hospital, with a registry enrolment figure of 20 participants, started 2025-11-04 and due to reach its primary completion in 2028-12-31. Interventions recorded: Tislelizumab + Anlotinib. Conditions listed: SCLC, Limited Stage. Primary outcome: Progression Free Survival (PFS); Overall Survival (OS). Lung eligibility wording from the registry: "Have histologically or cytologically confirmed small-cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), BeOne Medicines (formerly BeiGene), Tislelizumab and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Limited-stage small-cell lung cancer, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.